Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge MA YC W20 induced proximity medicines (molecular glues/PROTACs) targeting undruggable proteins; $16M Series A Jan 2025 Tomales Bay Capital competing with Arvinas and C4 Therapeutics for protein degradation oncology platform.
General Proximity is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $16 million in Series A funding in January 2025 led by Tomales Bay Capital — pioneering induced proximity medicines that work by bringing together disease-causing proteins to trigger their degradation or modulation, representing a next-generation therapeutic modality beyond traditional small molecule inhibitors and biologics. Founded in 2020, General Proximity combines computational chemistry, medicinal chemistry, and structural biology to design molecular glues and PROTACs (proteolysis-targeting chimeras) for previously undruggable targets in oncology and other disease areas — targeting the protein degradation mechanisms that cells use naturally to eliminate aberrant proteins.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.